{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:31:34Z","timestamp":1791379894725,"version":"4.3.3"},"reference-count":15,"publisher":"MedWorks Media","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Objectives:\nThe 22q11.2 deletion syndrome is one of the most prevalent genetic disorders and children suffering from this syndrome have been found to have a substantially greater risk for the development of schizophrenia and bipolar disorder. Psychiatric medications such as antipsychotics are commonly used in individuals with 22q11.2DS.\nExperimental Design:\nThis is a case of 13 years male young man suffering from 22q11.2 deletion syndrome. Since adolescence, he presented with behavioural disorders, aggression, verbal abuse, sleep disorders.\nPrincipal Observations:\nThe psychiatric examination confirmed the delusional idea, which was repeated in an obsessive way. There were also auditory hallucinations along with reference ideas. Aripiprazole was administered in 8 mg daily which gave more spectacular results and was better tolerated.\nConclusions:\nIn the present situation delusional ideas are no longer mentioned, but a cognitive deduction is found. Aripiprazole can be an effective pharmacological solution for the psychotic symptoms in patients suffering from 22q11DS.<\/jats:p>","DOI":"10.64719\/pb.4600","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:39:16Z","timestamp":1761046756000},"page":"35-39","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of Low-Dose Aripiprazole for Treatment of Psychotic Symptoms in a Patient with 22q11.2 Deletion Syndrome"],"prefix":"10.64719","volume":"50","author":[{"given":"Konstantinos","family":"Kontoangelos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Lazaratou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Economou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantina G.","family":"Yiannopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalambos C.","family":"Papageorgiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Lajiness-O\u2019Neil R, Beaulieu I, Asamoah A, Titus J, Bawle E, Ahmad S, Kirk J, Pollack R. The neuropsychological phenotype of velocardiofacial syndrome (VCFS): relationship to psychopathology. Archi Clin Neuropsychol. 2006;21(2):175\u2013184.","DOI":"10.1016\/j.acn.2005.09.001"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Gothelf D, Lombroso PJ. Genetics of childhood disorders: XXV. Velocardiofacial syndrome. J Am Acad Child Adolesc Psychiatry. 2001;40(4):489\u2013491.","DOI":"10.1097\/00004583-200104000-00021"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Eliez S, Antonarakis SE, Morris MA, Dahoun SP, Reiss AL. Prenatal origin of the deletion 22q11.2 and brain development in velocardiofacial syndrome. Archives of General Psychiatry. 2001;58(1):64\u201368.","DOI":"10.1001\/archpsyc.58.1.64"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Debbane M, Glaser B, David MK, Feinstein C, Eliez S. Psychotic symptoms in children adolescents with 22q11.2 deletion syndrome: neuropsychological and behaviroral implications. Schizophrenia Research. 2006;84(2\u20133):187\u2013193.","DOI":"10.1016\/j.schres.2006.01.019"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Dori N, Green T, Weizmsan A, Gothelf D. The effectiveness and safety of antipsychotic and antidepressan medications in individuals with 22q11.2 deletion syndrome. Journal of Child and Adolescent Psychopharmacology. 2017;27(1):83\u201390.","DOI":"10.1089\/cap.2014.0075"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Di Sciascio G, Riva MA. Aripiprazole: from pharmacological profile to Clinical use. Neuropsychiatr Dis Treat. 2015;13(11):2635\u20132647.","DOI":"10.2147\/NDT.S88117"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Jang J, Matson JL, Williams LW et al. Rates of comorbid symptoms in children with ASD, ADHD, and comorbid ASD and ADHD. Res Dev Disabil. 2013;34(8):2369\u20132378.","DOI":"10.1016\/j.ridd.2013.04.021"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Lin CE, Hwang KS, Hsieh PH, Chi CH, Tzeng NS. Treatment of schizophreniform disorder by aripiprazole in a female adolescent with 22q11.2 deletion syndrome. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(6):1141\u20131143.","DOI":"10.1016\/j.pnpbp.2010.05.011"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Jonas RK, Montojo CA, Bearden CE. The 22q11.2 deletion syndrome as a window into complex neuropsychiatric disorders over the lifespan. Biol Psychiatry. 2014;75(5):351\u2013360.","DOI":"10.1016\/j.biopsych.2013.07.019"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Bearden CE, Woodin MF, Wang PP, Moss E, McDonald-McGinn D, Zackai E, Emannuel B, Cannon TD. The neurocognitive phenotype of the 22q11.2 deletion syndrome: selective deficit in visual-spatial memory. J Clin Exp Neuropsychol. 2001;23(4):447\u2013464.","DOI":"10.1076\/jcen.23.4.447.1228"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Bassett AS, Chow EW, AbdelMalik P, Gheorghiu M, Husted J, Weksberg R. The schizophrenia phenotype in 22q11 deletion syndrome. Am J Psychiatry. 2003;160(9):1580\u20131586.","DOI":"10.1176\/appi.ajp.160.9.1580"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Murphy KC, Jones LA, Owen MJ. High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch Gen Psychiatry. 1999;56(10):940\u2013945.","DOI":"10.1001\/archpsyc.56.10.940"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Sparshatt A, Taylor D, Patel MX, Kapur S. A systematic review of aripriprazole-dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J Clin Psychiatry. 2017;71(11):1447\u20131456.","DOI":"10.4088\/JCP.09r05060gre"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Zheng W, Li XB, Xiang YQ et al. Aripirpazole for Tourette\u2019s syndrome: a systematic review and meta analysis. Hum Psychopharmacol. 2016;31(1):11\u201318.","DOI":"10.1002\/hup.2498"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Rizzo P, Pavone P. Aripiprazole for the treatment of irritability and aggression children and adolescents affected by autism spectrum disorders. Expert Rev Neurother. 2016;16(8):867\u2013874.","DOI":"10.1080\/14737175.2016.1211007"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:35:22Z","timestamp":1791315322000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/efficacy-of-low-dose-aripiprazole-for-treatment-of-psychotic-symptoms-in-a-patient-with-22q11-2-deletion-syndrome\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4600","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}